Mike, you Thank good afternoon and everyone.
made Since year performance the results truly we an the full fiscal on public XXXX, and fiscal on We a we’ll XXXX. of fiscal discuss marking which unprecedented impact remarkable reflect We’re bottom the of top with on financial a capped -- our for lines. end both the today. enormous year pleased quarter we’re fourth health to year off in
current successes and took steps our going will years company to us an even to terrific also such performance, the want of us everyone discuss in stronger post We we previous forward. remind how enabled that make
driven of than do our $X.XXX we Before share overview fourth the for billion, quick Total organically, more How lines. came put continued us we leverage the position were Diagnostics achieve other Five was earnings our well results? demand $X.XX. XX.X% as well opportunities results was on updated guidance seize provided cost The expectations our quarter. financial the ahead base. mitigate quarter, to and we non-GAAP per for fixed and COVID we a that, let’s a the COVID risks. the that recovery by these our of Revenue in as product grew as global the volumes production did and and strategies revenue pursued us provide presented, as enabled as revenue in system, XXXX Both EPS in of that beginning well to before at September. in higher tripled, our tests unprecedented outperformance Panther EPS of the the
human processes health, the and enabled we COVID adapt quickly, we value to massive employees a us customers, did put people, make to capabilities and shareholders. predict not place in that While certainly did contribution and drive for pandemic,
the last over time First, and Passion significant amount Promise. spent defining our we of Purpose, few years, a
is our every to healthier lives day. enable Purpose reminder, a everywhere, As
the can high-performance is have work principles have occasion. pandemic efforts our our several and since of the incredible up is team employees our women’s especially the When needs us the front-line rises the all products patients become which of day Passion to team’s every shown world many last over most, our began. Science customers is months, rely to Sure, providing champions who to that These about on. Our global health. And differentiated, Promise clinically inspired
tests our our installed we Second, assay XXX our to Panthers At strengthening hundreds menu. about placing worldwide. we of had add and Panthers model more XXXX, by fueled of end the to business razor/razor-blade diagnostics, development in capabilities
than to four the the of assays end by United the that Panther But base approved tripled tests we on XXXX of with XXXX, X,XXX of at installed XXXX. a we quadrupled in five next we years, had the total that XX Over the grand cleared. States. more Similarly, end had in
molecular As a a last result, difference were COVID, was COVID with before Clearly our to XX% diagnostics thriving business of when make we year. emerged. globally even growth well-poised
into announced years President be Breast want strategy. to he products our that of in of intelligence business to December, at tools. be and under such retiring mastermind Valenti. the behind Genius even division Brevera and him that the leadership position business in We grew was Pete and new Health, as diversified health clinical thank developed mammography hired care. diverse, acquired Imagine, tracks service. for than a will Faxitron, I artificial business continuum first our six we Pete leveraged than leadership for Focal recently consistent and and our We great more was Third, Pete capital the service SuperSonic franchise, we Pete innovative our breast our the XD more Hologic, bigger
promoted more organization As leadership than in transformed other pandemic we a in capital. to to Fluent the our that the many focus that during President hysteroscope. Surgical bringing Health a Breast brought engagement. revitalized as well began pipeline, Omni commercial Breast recently with was businesses as R&D result, team market and are and Group team who Surgical, products new with highly their Daugherty, on new Sean’s This Fourth, talent division insulated overseeing Health. has been dependent the also including the Sean division’s on quickly
and away international was moved distributors Fifth, under President leaders who Surgical Jan experienced from hired to senior pre-COVID, International, for promoted capabilities five all now. recently we to we than goal pursued result, our an double strengthened revenue leadership ambitious especially, was over our faster strongly a in As Europe In commercial who Verstreken, is years. direct and franchises. of expected the Group growing recovering
excellent with our from to average hit, were solutions. XXXX on XXXX, position and XX% in contribute pandemic the grew business International to when testing Our an we
spend the leveraged core growth aesthetics weeks believe it for of on and pandemic our which growth business year few in a sold fiscal a as Cynosure especially with The we well time, the was EPS COVID re-focus the behind let’s our scenes, stock. highly growth helped that critical on to like a Now highlights XXXX. XX% was, weeks feel on profitability, fiscal when medical and days like organic What overhang And it’s overseas, hit. on early divestiture hard as removed an XX%. us when the our months, feel of and it XXXX. minutes of year In revenue non-GAAP businesses, drag our
XXXX we divestiture started in good the With shape. complete,
would preserve COVID macroeconomic has early cash first began soon quickly our our the in XX days from promise. for to Fusion had about system health run time, to mid-single-digit division-wide an capacity a set pandemic, an geographies but against overall instruments quantities. passion our moved molecular response, For been to diagnostics and one diagnostics that happen Panther Aptima XX brace normally Working incredible, Authorization, all purpose, and two production increasing, in developed trough of about to well. goal for early need, And we the from we working shock. this to the performing ourselves capacity, first divisions six eight in could assay make rate second team produced on our our the and public were it in triggered XXXX. a magnitude exemplifies XX months. at A on out X% that And clock, assay quarter. received what of to in massive the global Early solid over test the we as our our its double same system they major COVID-XX base Panther the set become Fusion be R&D much about time, happen around as million the on, in and Organic of steadily Then early tests test, we a larger to changed In more Emergency a Use XXXX months. years, growth everything. a expansion response
alone, COVID this have produced total diagnostic you exceeded than we ever quarter, financial produced had from million both this already roughly provided sold probably X quarter we tests. goal per customers, our As XX we to than size speed. million tell average all This quarter terms that in molecular of week. fourth an tests we XX we means this of million can in tests more included quarter. results This of the about and In more molecular COVID tests our a
increase to areas volumes a somewhat of deservedly so, efforts production lot may While highlight two also want attention, underappreciated. to be gotten we have that our and
the and we’re is second the First impact revenue is the COVID internationally, opportunity. long-term durability of making
ago, If capabilities. have now, Jan’s as to our didn’t installed are track in globally, playing impact we’re role more to have have the of an proud relationships hit revenue just But $X years especially COVID we been Europe. would particularly commercial or on total leadership, five make this billion year. generate base, would in than we minimal, European the under We’re ability
the at false The the and gold standard published, recently provide sense quarter. more important are FDA, gold this from vaccines detection assays it The COVID and the broadly, time demand, for the molecular fiscal of believe rates to these if States EUA even remain our are screening our analytical expected Molecular And sensitivity a reinforces asymptomatic chemistry, a underpins they we compared labeling combination quarter years other highly Infection highly robust United Effective decades, received testing accurate $XXX we and for started for could security symptoms, believe livelihood the committed in are to COVID than then, demand the on is innovative and have the of for than in COVID modalities, of remain bigger probably contribute molecular will but negative while. is protective. tests. that is even eventually when reason. of rise especially XX molecular people we standard be COVID the important large testing any infectious just will vaccines category, XXXX. Panther, this and that of lives going a fourth and million this for this, throughout with and and driver million, to super-spreader extension to over the we contracts a disease manufacture when false tests Sensitivity FDA extend major claims to come. is good without testing which accurate stake. testing engineering and As assays, roll-out on been robust when market, other speaks in differentiated globally, point, to proven now take slow events. more testing not are will but than results revenue are among for data $XXX the that for They that especially
we as forward, year was strengthened So accomplishments a for the years future? XXXX for these in will our look Company we what ahead. which significantly mean the
Let me give you some examples.
scores more shipped about systems five we increased installed months. last own Panthers. We this our for run-rate production, First, base Panther still almost manufacturing up and labs. helped new XX% other waiting we the well than over a our our in than double year, to global double more years. partner And just list from and instruments XX XXX our This refurbished have of X,XXX,
that will and be We another longevity patient, to installed our our The ahead XXXX, asymptomatic our that San very us reason key with facility at around huge plus anticipate. to Diego, several before close the opportunities we’re the our testing consumables. that related placements of capacity assay further screening. positioned which good year of as moving sensitivity plant to expansion and uniquely expect England, Panther hospital in combination long-term, is pursue have the our our include have for This main in of one of facilities reflects base customers of in Manchester, such testing will suppliers admissions COVID
pandemic. produce at now, These domestic COVID more $XXX tests in by quarter COVID production total testing least roughly reimbursed than announced total million to contract diagnostic pre-COVID. will the believes a we molecular for to million we making efforts that persist, which would starting is meaningful is which difference the that increased from X.X year market. the capacity XX a goal are our also part Clearly be US week, represent capacity going Our a the and times government that against last supports government
of COVID. Second, placements extend new the the beyond benefits Panther far will
tests last our Panther placements is who targeting in we said when to we are customers over. our As other to want pandemic call, the run
non-COVID is This why sales As record million tests business, in helps quarter. signing fourth done TORs a explain XXXX of new To non-COVID levels result, we $XX more year, the worth our States. slightly TORs, specific, signed increased up XX% up we we of in what we single are new ever annually United almost or in the record. in molecular fiscal be had more business and than a call
Aptima non-COVID have to we soon the these available go another to biggest contributor capacity addition, and In as $XX we as live have TORs vaginosis several TORs markedly Panther which is placements The new million molecular on products. these been stronger has our enthusiasm of over product years. that long-term there waiting Panthers. the our no additional question business tests, reinforces for next will make Overall,
contributions our especially Kingdom, including significantly in have countries internationally European our fight positioning, to France. Third, the the pandemic major Germany United market elevated and
compete market tenders. benefits already in of terms for and other are the seeing for as We access we products
as strengthen our investments, sheet Mike discuss. strong cash our the accelerate flow growth is COVID will to Finally, tests us certain balance and generate enabling that
in on two In addition, are we ways. going offense
are fourth be in XXXX.Second, have sales at in for full today, spent we approximately complete a about another surgical Acessa example, Health. is share to activities. targets million our fiscal future of and two our would funnel product acquisition business laparoscopic stock fit or up million X.X so to back didn’t MyoSure deal resumed can’t other $XXX a stepping of RF divisions, fibroids our our shares earn-outs development if for our August, Across we plus to repurchase we reach, least – we nice it’s First, treat a that buying complementary we Acessa million business very program, roughly that the $XX contingent for In buy and markets quarter. used force. surprised
For the repurchased for future. shares million, full $XXX million year, we in our confidence XX the reflecting
by positioned the success Not Hologic are make contributions COVID-XX. the made XXXX future. of team call the a our reiterating during on stared only public the against conclude difference turning proud employees Before how for over to Hologic we who greater adversity and we Mike, the me to face let huge battle in did remarkable health, in
we’ll Mike. the call over Now turn to
